Inhibrx reported that its monoclonal antibody ozekibart met the primary endpoint in a registrational phase II study for unresectable or metastatic chondrosarcoma, producing statistically significant improvement in progression‑free survival versus placebo. The San Diego biotech said the topline result prompted plans to pursue a biologics license application in the second half of 2026. Company releases and trading reactions showed a sharp market response. Inhibrx described the dataset as sufficient to support regulatory discussions and outlined next steps toward a BLA submission; investigators noted the rarity of the indication and the limited current treatment options.